Compare Gilead Sciences, Inc. (GILD) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs MINISO Group Holding Ltd — how do they compare? Gilead Sciences, Inc. trades at $134.82 (market cap $163.51B), while MINISO Group Holding Ltd trades at $13.13 (market cap $3.73B). The key difference: Gilead Sciences, Inc. is far larger — about 43.8× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (5.28%). Which is the better fit depends on your goals.
| GILD | MNSO | |
|---|---|---|
Market Cap | $163.51B | $3.73B |
Sector | Health | Technology |
52-Week High | $155.80 | $26.63 |
52-Week Low | $108.22 | $11.30 |
Enterprise Value | $178.05B | $4.39B |
Dividend Yield | 2.49% | 5.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
MNSO trades at $12.92, up 12.06% in the past 24 hours, with a bullish technical signal and strong recent earnings beat in Q1 2026. The company reported 28.5% revenue growth and announced a HK$2 billion share repurchase program, signaling management confidence. Valuation metrics appear reasonable with a P/E of 12.84 and P/S of 1.16, while profitability improved with net income margin reaching 8.98% for 2026.
The outlook remains positive given strong fundamentals and bullish analyst sentiment, though risks include margin compression from overseas expansion costs and competitive pressures in the retail sector. The stock offers growth potential with solid financial health, but investors should monitor execution on international growth strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
